ISRCTN15606951进行中（未招募）未知
Response evaluation in myeloma patients using integrated 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography/magnetic resonance imaging (PET/MRI)
适应症
试验速览
- 阶段
- 未知
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Newly diagnosed with myeloma
排除标准
- •1. Contraindication to PET/CT or PET/MR
- •2. Unable to provide informed consent.
研究者
相似试验
已完成
不适用
Study of the outcome of patients with myeloma nephropathy on treatment with High Cut Off Haemodialysis (HCO-HD) in addition to chemotherapy at the Launceston General HospitalBlood - Haematological diseasesMultiple MyelomaACTRN12612000024842Clifford Craig Medical Trust Fund10
进行中（未招募）
不适用
Randomised comparisons, in myeloma patients of all ages, of thalidomide, lenalidomide, carfilzomib and bortezomib induction combinations, and of lenalidomide and combination lenalidomide vorinostat as maintenance - Myeloma XIewly diagnosed patients with symptomatic myelomaMedDRA version: 16.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864EUCTR2009-010956-93-GBniversity of Leeds4,000
已完成
不适用
The GMMG-HD5 trial: bortezomib-based induction prior to high dose therapy and autologous stem cell transplantation followed by lenalidomide-based consolidation and maintenance therapy in patients with multiple myelomaCancerMultiple myelomaISRCTN05745813Heidelberg University (Germany)504
进行中（未招募）
不适用
Comparative Trial inMultiple Myeloma Patients of Oral Ibandronic Acid versus Intravenous Zoledronate: a phase III studyMultiple MyelomaEUCTR2005-003770-23-ATF. Hoffmann-La Roche Ltd424
进行中（未招募）
1 期
Impact of lenalidomide on immune cell expression in multiple myelomaMedDRA version: 21.0Level: LLTClassification code 10028228Term: Multiple myelomaSystem Organ Class: 100000004864Multiple MyelomaEUCTR2021-000987-31-FRCHU Rennes22